Akihisa Mori

Summary

Affiliation: Kyowa Hakko Kogyo Co
Country: Japan

Publications

  1. ncbi request reprint Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists
    Akihisa Mori
    Pharmaceutical R and D Division, Kyowa Hakko Kogyo Co, Ltd, Tokyo, Japan
    Neurology 61:S44-8. 2003
  2. ncbi request reprint Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats
    Tomomi Shindou
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Sunto, 411 8731, Shizuoka, Japan
    Neurosci Lett 352:167-70. 2003
  3. pmc Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus
    Tomomi Shindou
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Sunto, Shizuoka 411 8731, Japan
    Br J Pharmacol 136:296-302. 2002
  4. ncbi request reprint Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain
    Shiro Aoyama
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Brain Res 953:119-25. 2002
  5. doi request reprint Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Southfield, MI 48034, USA
    Ann Neurol 63:295-302. 2008
  6. ncbi request reprint [Recent and potential drug candidates for treatment of Parkinson's disease]
    Tomoyuki Kanda
    Nihon Yakurigaku Zasshi 131:275-80. 2008

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists
    Akihisa Mori
    Pharmaceutical R and D Division, Kyowa Hakko Kogyo Co, Ltd, Tokyo, Japan
    Neurology 61:S44-8. 2003
    ..Blockade of these modulatory functions by A2A antagonists could counteract excessive striatopallidal neuronal activity provoked by striatal dopamine depletion in patients with PD, leading to a reversal of parkinsonian motor deficits...
  2. ncbi request reprint Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats
    Tomomi Shindou
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Sunto, 411 8731, Shizuoka, Japan
    Neurosci Lett 352:167-70. 2003
    ..These results demonstrate that the target neurons of adenosinergic modulation via A(2A) receptors in the GP are the striatopallidal MSNs...
  3. pmc Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus
    Tomomi Shindou
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Sunto, Shizuoka 411 8731, Japan
    Br J Pharmacol 136:296-302. 2002
    ....
  4. ncbi request reprint Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain
    Shiro Aoyama
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Brain Res 953:119-25. 2002
    ....
  5. doi request reprint Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Southfield, MI 48034, USA
    Ann Neurol 63:295-302. 2008
    ..Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A(2A) receptor antagonist, istradefylline, shows promise for the treatment of PD...
  6. ncbi request reprint [Recent and potential drug candidates for treatment of Parkinson's disease]
    Tomoyuki Kanda
    Nihon Yakurigaku Zasshi 131:275-80. 2008